The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
CTLA‐4Ig (belatacept) blocks the CD80/CD86 ligands for both CD28 and CTLA‐4; thus, in addition to the intended effect of blocking CD28‐mediated costimulation, belatacept also has the unintended effect of blocking CTLA‐4–mediated coinhibition. Recently, anti‐CD28 domain antibodies (dAb) that selectively target CD28 while leaving CTLA‐4 intact were shown to more effectively inhibit alloimmune responses...